NuVasive (NUVA) acquired Vertera Spine, developer of porous-PEEK-based spinal interbody fusion devices. Transaction terms were not disclosed.
With the purchase, NUVA is now the sole device company offering both PEEK and titanium porous interbody devices to suit surgeon preference and encourage bone ingrowth. NUVA will sell COHERE® cervical and COALESCE™ lumbar interbody fusion systems in the U.S., and plans to apply porous PEEK technology to its product development pipeline.
Unlike a surface treatment, the Scoria™ biomaterial on which Vertera’s devices are based is grown directly out of solid PEEK material, creating a seamless surface-to-solid material interface that is reportedly more durable than metal coatings and 2x stronger under shear loading than trabecular bone.
COHERE received FDA 510(k) clearance at the end of 2015 and beta-launched in 2Q16. It is the only product approved for use under a recently-issued CMS ICD-10 code for a radiolucent porous interbody fusion device, indicating CMS’ recognition of the potential clinical and tracking benefits of porous PEEK.
COALESCE received FDA clearance at the close of 2Q17 for use in anterior, transforaminal, posterior and lateral lumbar fusion.
As well as securing a unique porous PEEK technology, the purchase also supports NUVA in its plan to log $1 billion in 2017 revenue. NUVA’s last strategic acquisitions to broaden its capabilities occurred in 2016, with purchases of Ellipse Technologies, Biotronic NeuroNetwork and LessRay software.
NuVasive (NUVA) acquired Vertera Spine, developer of porous-PEEK-based spinal interbody fusion devices. Transaction terms were not disclosed.
With the purchase, NUVA is now the sole device company offering both PEEK and titanium porous interbody devices to suit surgeon preference and encourage bone ingrowth. NUVA will sell COHERE®...
NuVasive (NUVA) acquired Vertera Spine, developer of porous-PEEK-based spinal interbody fusion devices. Transaction terms were not disclosed.
With the purchase, NUVA is now the sole device company offering both PEEK and titanium porous interbody devices to suit surgeon preference and encourage bone ingrowth. NUVA will sell COHERE® cervical and COALESCE™ lumbar interbody fusion systems in the U.S., and plans to apply porous PEEK technology to its product development pipeline.
Unlike a surface treatment, the Scoria™ biomaterial on which Vertera’s devices are based is grown directly out of solid PEEK material, creating a seamless surface-to-solid material interface that is reportedly more durable than metal coatings and 2x stronger under shear loading than trabecular bone.
COHERE received FDA 510(k) clearance at the end of 2015 and beta-launched in 2Q16. It is the only product approved for use under a recently-issued CMS ICD-10 code for a radiolucent porous interbody fusion device, indicating CMS’ recognition of the potential clinical and tracking benefits of porous PEEK.
COALESCE received FDA clearance at the close of 2Q17 for use in anterior, transforaminal, posterior and lateral lumbar fusion.
As well as securing a unique porous PEEK technology, the purchase also supports NUVA in its plan to log $1 billion in 2017 revenue. NUVA’s last strategic acquisitions to broaden its capabilities occurred in 2016, with purchases of Ellipse Technologies, Biotronic NeuroNetwork and LessRay software.
Copy to clipboard 
